Advice

following a full submission:

rituximab (MabThera®) is accepted for restricted use within NHS Scotland.

Indication under review: Rituximab maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

SMC restriction: for maintenance treatment in follicular lymphoma patients who have responded to induction with rituximab plus chemotherapy.

Rituximab significantly increased progression free survival following a response to induction therapy in patients with previously untreated follicular lymphoma compared with observation alone. Longer follow up is required to establish benefit in overall survival.

Download detailed advice111KB (PDF)

Download

Medicine details

Medicine name:
rituximab (Mabthera)
SMC ID:
675/11
Indication:
Follicular lymphoma patients responding to induction therapy
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published
07 February 2011